Abstract
Biodegradable polymeric materials are the most common carriers for use in drug delivery systems. With this trend, newer drug delivery systems using targeted and controlled release polymeric nanoparticles (NPs) are being developed to manipulate their navigation in complex in vivo environment. However, a clear understanding of the interactions between biological systems and these nanoparticulates is still unexplored. Different studies have been performed to correlate the physicochemical properties of polymeric NPs with the biological responses. Size and surface charge are the two fundamental physicochemical properties that provide a key direction to design an effective NP formulation. In this critical review, our goal is to provide a brief overview on the influences of size and surface charge of different polymeric NPs in vitro and to highlight the challenges involved with in vivo trials.
Highlights
Manufacturing effective drug delivery system is a critical challenge in nanomedicine since nanocarriers are expected to reach and accumulate in the site of interest
The nanomedicine platforms could serve as a drug delivery system that is able to transport a high dose of therapeutics selectively to the desired site of action
This review provides details on the fate of different polymeric NPs and will discuss how the size and surface charge of polymeric NPs are involved in desired effects for both in vitro and in vivo applications
Summary
Manufacturing effective drug delivery system is a critical challenge in nanomedicine since nanocarriers are expected to reach and accumulate in the site of interest. (2016) Effects of Size and Surface Charge of Polymeric Nanoparticles on in Vitro and in Vivo Applications. The in vitro and in vivo fate of NPs is depended on uniformity of particle size and zeta potential Change in these properties has significant biological implications on cellular internalization, pharmacokinetics, and bio-distribution [2]. These characteristics of NPs facilitate the opportunities for therapeutic application, which can be confirmed by in vitro and in vivo studies [3]. This review provides details on the fate of different polymeric NPs and will discuss how the size and surface charge of polymeric NPs are involved in desired effects for both in vitro and in vivo applications. Abbreviation: BCEC: Brain capillary endothelial cells; BSA: Bovine Serum Albumin; DCs: Dendritic Cells; HASMCs: Human arterial smooth muscle cells; HA-VSMCs: Human aortic vascular smooth muscle cells; HMSCs: Human mesenchymal stem cells; HUVECs: Human umbilical vein endothelial cells; MOEC: Murine ovarian endothelial cells; NAcHis-GC: N-acetyl histidine conjugated glycol chitosan nanoparticles); P (MDS-co-CES): Poly (methyldiethene-aminesebacate)-co-[(cholesterylox-ocarbonylamidoethyl) methylbis (ethylene) ammonium bromide] sebacate; PBMCs: Peripheral blood mononuclear cells; PBS: Phosphate buffer saline; PEG: Poly (ethylene glycol); PEG-PHDCA: Poly (methoxypolyethyleneglycol cyanoacrylate-co-hexadecylcyanoacrylate); PEMA: Poly (ethylene-maleic anhydride); PEO-b-PMA: Poly (ethylene oxide)-b-poly (methacrylic acid); PLA: Poly (lactic acid); PMB: Poly [2-methacryloyloxyethyl phosphorylcholine (MPC)-co-n-butyl methacrylate (BMA); PMBH: Poly [2-methacryloyloxyethyl phosphorylcholine (MPC)-co-n-butyl methacrylate (BMA)-co-methacryloylhydrazide (MH)]; PVA: Polyvinyl Alcohol; RBECs: Rat brain endothelial cells; TPGS: Tocopheryl polyethylene glycol succinate; VSMCs: Vascular smooth muscle cells; WGA: Wheat germ agglutinin
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
